FIELD: pharmacology.
SUBSTANCE: new pharmaceutical product is used that includes compound A at a dose of 800 to 3000 mg per day, daily for 5 days on days 1 to 5 of the treatment cycle followed by a break of 23 days.
EFFECT: method allows to increase the effectiveness of treatment.
9 cl, 4 tbl, 1 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTITUMOUR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE | 2014 |
|
RU2657604C2 |
| METHODS FOR COMBINATION THERAPY OF PROLIFERATIVE DISEASES | 2011 |
|
RU2577278C2 |
| USE OF ERIBULIN AND LENVATINIB AS COMBINATION THERAPY FOR TREATMENT OF CANCER | 2014 |
|
RU2672585C2 |
| METHOD INCLUDING FIXED FRACTIONAL DOSING OF CEDIRANIB | 2017 |
|
RU2740849C2 |
| DISCONTINUOUS INTRODUCTION OF MDM2 INHIBITOR | 2015 |
|
RU2695228C2 |
| DOSE AND INJECTION MODE FOR INHIBITORS OF INTERACTION OF HDM2 WITH P53 | 2017 |
|
RU2762573C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2015 |
|
RU2708374C2 |
| LOW-DOSE ANTITUMOR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE | 2014 |
|
RU2668125C2 |
| METHOD FOR TREATING CANCER | 2002 |
|
RU2284184C2 |
| HDM2-P53 INHIBITOR AND BCL2 INHIBITOR INTERACTION COMBINATIONS AND THEIR USE FOR CANCER TREATMENT | 2019 |
|
RU2793123C2 |
